-
Pakistan 'have underperformed' says Agha after T20 World Cup exit
-
Under-strength Toulouse overpower Montauban in Top 14
-
Vietnam AI law takes effect, first in Southeast Asia
-
Brazil's Lula visits flood zone as death toll from landslides hits 70
-
New Zealand into T20 World Cup semis as Sri Lanka avoid big Pakistan loss
-
Medvedev wins Dubai title as Griekspoor withdraws
-
First Yamal hat-trick helps Liga leaders Barcelona beat Villarreal
-
Liverpool hit five past West Ham, Haaland-less City face Leeds test
-
Van der Poel romps to cobbled classic win
-
Republicans back Trump, Democrats attack 'illegal' Iran war
-
Madonna is surprise attraction at Dolce & Gabbana Milan show
-
Farhan keeps Pakistan hopes alive as they post 212-8 against Sri Lanka
-
Afghanistan says civilians killed in Pakistan air strikes
-
Tug of war: how US presidents battle Congress for military powers
-
Residents flee as Iran missiles stun peaceful Gulf cities
-
Streets empty and shops close as US strikes confirm Iranian fears
-
Israelis shelter underground as Iran fires missiles
-
Bournemouth held by Sunderland in blow to European bid
-
VAR expanded to include second bookings and corners for World Cup
-
Iranians in Istanbul jittery but jubilant at US, Israeli strikes
-
Congo-Brazzaville president vows to keep power as campaign kicks off
-
US, Israel launch strikes on Iran, Tehran hits back across region
-
Germany's Aicher wins women's super-G in Soldeu
-
Fight against terror: Trump threatens Tehran's mullahs
-
US and Israel launch strikes on Iran, explosions reported across region
-
Iran's Khamenei: ruthless revolutionary at apex of Islamic republic
-
In Iran attack, Trump seeks what he foreswore -- regime change
-
Climate change forces facelift for Michelangelo masterpiece
-
Trump says US aims to destroy Iran's military, topple government
-
Acosta wins season-opening MotoGP sprint after Marquez penalty
-
US and Israel launch strikes against Iran
-
Afghanistan says Pakistan fighter jet down as cross-border strikes flare
-
Kerr says only '85 percent' fit for Women's Asian Cup
-
Messi's Inter Miami to visit White House: US media
-
Thunder beat Nuggets in overtime on Gilgeous-Alexander's return
-
'It's surreal': Zimbabwe superfans revel in unexpected ride to India
-
New 'Wuthering Heights' film unleashes fresh wave of Bronte-mania
-
US backs Pakistan's 'right to defend itself' after strikes on Afghanistan
-
Bezzecchi beats Marquez to pole at season-opening Thailand MotoGP
-
OpenAI strikes Pentagon deal with 'safeguards' as Trump dumps Anthropic
-
Oscar-nominated 'F1' sound engineers recreate roar of racetrack
-
15 dead as cash-packed military plane crashes in Bolivia
-
Costa Rica's Grynspan pledges reform in bid for UN chief job
-
Former All Black Bridge hailed for influence at Western Force
-
'Sinners' vampires inspired by animals, says Oscar hopeful makeup artist
-
For Oscar nominee Stellan Skarsgard, good cinema is like slow food
-
'Brilliant industry' sees Reds down Highlanders in Super Rugby
-
Neil Sedaka, US singer and songwriter, dies age 86
-
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM EST
-
Understanding Common Dental Issues That Develop Over Time in Richardson, TX
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
P.Stevenson--AMWN